Resolution of Macular Oedema in Diabetic Patients Following Avastin (Bevacizumab) Intravitreal Therapy

Authors

  • Ata-ur-Rehman, Saba Alkhairy, Farnaz Siddiqui, Mirza Shafiq Ali Baig

DOI:

https://doi.org/10.36351/pjo.v33i2.63

Abstract

Purpose: To estimate the effectiveness of intravitreal Avastin (bevacizumab) treatment in the reduction of macular oedema in diabetic patients.

Study Design: Prospective Cohort study.

Place Duration of study: Outpatient department (OPD) of the Ophthalmology department of Liaquat National Hospital (LNH) between the period April 2013 March 2015.

Material Methods: A total of 66 eyes of 44 patients (both type 1 type 2 diabetics) were selected who were advised their first intraocular Avastin in one or both eyes with clinically visible angiographically confirmed macular oedema and those who did not have a prior history of grid laser photocoagulation. All subjects were treated by intravitreal avastin (bevacizumab) 1.25 mg injection. Best-corrected visual acuity, slit lamp examination and fundus fluorescein angiography were examined before after intravitreal injection.

Results: A total of 66 eyes of 44 patients (both type I Type II diabetes) without any prior history of Avastin were included in the study. There were 26 (59%) males 18 (41%) females. The edema was seen completely resolved in 8 patients (12.2%), partially resolved 44 (66.7%) not resolved in 14 (21.21%). There was no adverse reaction seen in any   eye except four eyes had mild anterior chamber inflammation which were treated with topical corticosteroid and one eye developed sub-conjunctival haemorrhage. The visual   acuity improved in 59 out of 66 eyes (89%) based on the increased number of lines read by the patient on Snellen chart and in only 7 eyes there was no improvement during a mean follow-up period of 6 months.

Conclusion: Intravitreal bevacizumab injection provides significant improvement in visual acuity as well as reduction of macular oedema therefore may consider as a primary treatment of diabetic macular oedema.

Keywords: Anti-vascular endothelial growth factor; Bevacizumab; Diabetic macular edema; Diabetic retinopathy.

Downloads

Published

01-06-2017

How to Cite

1.
Farnaz Siddiqui, Mirza Shafiq Ali Baig A- ur-RSA. Resolution of Macular Oedema in Diabetic Patients Following Avastin (Bevacizumab) Intravitreal Therapy. pak J Ophthalmol [Internet]. 2017 Jun. 1 [cited 2022 Aug. 17];33(2). Available from: https://pjo.org.pk/index.php/pjo/article/view/63

Issue

Section

Review Articles